What is the most effective way to quit smoking?

The most effective approach combines pharmacotherapy with behavioral support (counseling, quitline, support group). Varenicline (Chantix) has the highest single-agent quit rate (~33% at 6 months). Combination NRT (patch + short-acting form like gum or lozenge) is similarly effective. Adding behavioral counseling (at least 4 sessions) approximately doubles the quit rate regardless of medication choice. For most smokers, especially those with FTND ≥5, medication plus counseling is recommended.

What is the Heaviness of Smoking Index?

The HSI is a 2-item subscale using only Q1 (time to first cigarette) and Q4 (cigarettes per day). It ranges from 0–6 and has been validated as a brief alternative to the full FTND. HSI ≥4 indicates heavy smoking/high dependence. It's useful in busy clinical settings where administering the full 6-item FTND isn't practical, and it predicts cessation outcomes nearly as well as the full scale.

Why does time to first cigarette matter so much?

Smoking within 30 minutes of waking indicates that overnight nicotine withdrawal symptoms are strong enough to drive immediate smoking behavior. This reflects high receptor occupancy and neuroadaptation — the brain "needs" nicotine to function normally. Smokers who smoke within 5 minutes of waking have significantly lower quit rates without pharmacotherapy and experience more severe withdrawal symptoms (irritability, anxiety, difficulty concentrating, cravings).

What happens during nicotine withdrawal?

Withdrawal symptoms typically: begin within 2–4 hours of last cigarette, peak at 2–3 days, and gradually improve over 2–4 weeks. Common symptoms: intense cravings (can persist for months), irritability, anxiety, difficulty concentrating, restlessness, increased appetite, insomnia, and depressed mood. Pharmacotherapy significantly reduces the severity of these symptoms. The acute phase is hardest, but many quitters report lingering cravings for months, triggered by situations previously associated with smoking.

Is vaping/e-cigarettes an effective cessation tool?

E-cigarettes are not FDA-approved cessation aids, and evidence is mixed. Some trials show higher quit rates than NRT, while others show no benefit. Concerns include: maintaining nicotine addiction (switching rather than quitting), unknown long-term health effects, dual use (vaping + smoking), and youth initiation. Major medical organizations (ACS, AHA) acknowledge e-cigarettes may be less harmful than cigarettes but don't recommend them as first-line cessation tools. FDA-approved medications (varenicline, NRT, bupropion) remain the standard of care.

Should low-dependence smokers still use medication?

Even low-dependence smokers (FTND 0–2) benefit from pharmacotherapy — NRT approximately doubles quit rates across all dependence levels. However, low-dependence smokers also have reasonable quit rates with behavioral support alone (~14–20%). The decision depends on patient preference, prior quit attempts (those who've failed behavioral-only approaches should try medication), and clinical judgment. Brief NRT (gum, lozenge) is often sufficient for low-dependence smokers who opt for pharmacotherapy.

Fagerström Test for Nicotine Dependence (FTND) Calculator

Assess nicotine dependence severity with the 6-item Fagerström Test. Get FTND score, dependence level, pharmacotherapy recommendations, and cessation treatment guidance.

⚠️ Medical Disclaimer: The FTND is a validated screening tool for nicotine dependence. It guides treatment intensity but does not replace clinical assessment. All smokers benefit from cessation regardless of dependence level.

Answered: 0 / 6 — Please answer all questions about your current smoking habits.

1. How soon after you wake up do you smoke your first cigarette?

2. Do you find it difficult to refrain from smoking in places where it is forbidden?

3. Which cigarette would you hate most to give up?

4. How many cigarettes per day do you smoke?

5. Do you smoke more frequently during the first hours after waking than during the rest of the day?

6. Do you smoke even when you are so ill that you are in bed most of the day?

Presets:

Planning notes, formulas, and examples

About the Fagerström Test for Nicotine Dependence (FTND) Calculator

The Fagerström Test for Nicotine Dependence (FTND) Calculator implements the standard 6-item validated questionnaire for assessing the intensity of physical nicotine dependence in cigarette smokers. Originally developed by Karl-Olov Fagerström in 1978 as the Fagerström Tolerance Questionnaire (FTQ), it was revised to the current FTND form by Heatherton et al. in 1991 to better measure physical dependence rather than overall smoking behavior.

The FTND score (0–10) is a worksheet-style dependence measure that can help frame quit support and withdrawal planning. Two items are particularly predictive: time to first cigarette after waking (the strongest single predictor of dependence) and number of cigarettes per day. These two items form the Heaviness of Smoking Index (HSI), a validated 2-item brief alternative used when the full FTND is impractical.

Higher FTND scores indicate greater physical dependence and may justify more intensive cessation support. This page is meant to help organize that discussion, not to prescribe a single medication or program.

When This Page Helps

The FTND is useful because it turns vague smoking-history discussion into a structured severity score you can compare over time or use to frame a cessation conversation. On this page, the score is presented as a worksheet for support planning rather than a stand-alone treatment order.

How to Use the Inputs

Answer all 6 questions about your current smoking habits.
Questions address time to first cigarette, difficulty refraining, which cigarette you'd miss most, daily consumption, morning smoking pattern, and smoking when ill.
Review your FTND score, dependence classification, and treatment recommendations.
Note the Heaviness of Smoking Index (HSI) subscale from questions 1 and 4.
Discuss pharmacotherapy options with your healthcare provider based on the results.

Formula used

FTND Total = Sum of 6 items

Q1: Time to first cigarette: ≤5 min=3, 6–30 min=2, 31–60 min=1, >60 min=0
Q2: Difficulty refraining: Yes=1, No=0
Q3: Hardest to give up: First morning=1, Other=0
Q4: Cigarettes/day: ≤10=0, 11–20=1, 21–30=2, ≥31=3
Q5: Morning smoking heavier: Yes=1, No=0
Q6: Smoking when ill: Yes=1, No=0

HSI (Heaviness of Smoking Index) = Q1 + Q4 (range 0–6)
Score range: 0–10

Example Calculation

Result: FTND Score: 8/10 — High Dependence. Varenicline recommended + intensive counseling.

Total score: 2+1+1+2+1+1 = 8. HSI: 2+2 = 4/6. This indicates high physical nicotine dependence. The early time to first cigarette and continued smoking when ill are markers of strong physical dependence. Varenicline is the preferred pharmacotherapy, combined with at least 4 counseling sessions. Combination NRT (21mg patch + gum/lozenge) is an effective alternative.

Tips & Best Practices

Time to first cigarette is the single strongest predictor of dependence — smoking within 5 minutes of waking indicates high dependence.
The HSI (Q1 + Q4 only) is a valid brief screen when the full FTND isn't feasible — scores ≥4 suggest high dependence.
Every smoker should be offered cessation support regardless of FTND score — even lower scores can benefit from help.
Pack-years (packs/day × years of smoking) should be calculated separately for lung cancer screening eligibility (≥20 pack-years per USPSTF).
Combining pharmacotherapy with behavioral counseling improves quit rates compared with either alone.
The FTND is specific to cigarette smoking — use the HONC (Hooked on Nicotine Checklist) for adolescents and the Penn State Cigarette Dependence Index for additional assessment.

History and Validation

The original Fagerström Tolerance Questionnaire (FTQ, 1978) contained 8 items and measured both behavioral and physical dependence. Heatherton et al. (1991) revised it to the FTND by removing two items with low item-total correlations (inhaling depth and nicotine/tar yield) and modifying the scoring of two others. The FTND has been validated against biochemical markers (cotinine levels, exhaled CO), withdrawal severity, and cessation outcomes in dozens of studies across diverse populations.

Pharmacotherapy Evidence

A Cochrane review of 150+ trials established the hierarchy: Varenicline (OR 2.88 vs. placebo) > Combination NRT (OR 2.73) > Single NRT (OR 1.84) ≈ Bupropion (OR 1.82). Combining any medication with behavioral counseling (≥4 sessions) adds ~50% to the quit rate. Cost-effectiveness analyses consistently show cessation treatments are among the most cost-effective medical interventions available. Even modest improvements in quit rates produce significant health benefits given the enormous health burden of smoking.

Beyond the FTND

The FTND has limitations: it doesn't assess psychological/social dependence, behavioral habits, or motivation to quit. Complementary tools include: the Cigarette Dependence Scale (CDS-12, broader dependence measure), Stages of Change assessment (readiness to quit), Wisconsin Inventory of Smoking Dependence Motives (WISDM, detailed motivational profile), and the Glover-Nilsson Smoking Behavioral Questionnaire (behavioral habit strength). A comprehensive cessation assessment integrates multiple dimensions beyond physical dependence.

Sources & Methodology

Last updated: March 28, 2026

Methodology

This worksheet scores the six standard FTND questions and also shows the Heaviness of Smoking Index (HSI) from the first and fourth items. It is a screening and planning aid for smoking-cessation conversations, not a diagnosis or a treatment order.

The result is best used to compare dependence severity and to choose the level of cessation support, counseling, or medication review that may be appropriate.

Sources

Heatherton TF et al. The Fagerström Test for Nicotine Dependence — Revision paper for the current 6-item FTND.
Heaviness of Smoking Index validation literature — Background for the abbreviated two-item subscale.
CDC smoking cessation resources (Centers for Disease Control and Prevention) — General cessation-planning context.

Frequently Asked Questions

The most effective approach combines pharmacotherapy with behavioral support (counseling, quitline, support group). Varenicline (Chantix) has the highest single-agent quit rate (~33% at 6 months). Combination NRT (patch + short-acting form like gum or lozenge) is similarly effective. Adding behavioral counseling (at least 4 sessions) approximately doubles the quit rate regardless of medication choice. For most smokers, especially those with FTND ≥5, medication plus counseling is recommended.
Smoking within 30 minutes of waking indicates that overnight nicotine withdrawal symptoms are strong enough to drive immediate smoking behavior. This reflects high receptor occupancy and neuroadaptation — the brain "needs" nicotine to function normally. Smokers who smoke within 5 minutes of waking have significantly lower quit rates without pharmacotherapy and experience more severe withdrawal symptoms (irritability, anxiety, difficulty concentrating, cravings).
Withdrawal symptoms typically: begin within 2–4 hours of last cigarette, peak at 2–3 days, and gradually improve over 2–4 weeks. Common symptoms: intense cravings (can persist for months), irritability, anxiety, difficulty concentrating, restlessness, increased appetite, insomnia, and depressed mood. Pharmacotherapy significantly reduces the severity of these symptoms. The acute phase is hardest, but many quitters report lingering cravings for months, triggered by situations previously associated with smoking.
E-cigarettes are not FDA-approved cessation aids, and evidence is mixed. Some trials show higher quit rates than NRT, while others show no benefit. Concerns include: maintaining nicotine addiction (switching rather than quitting), unknown long-term health effects, dual use (vaping + smoking), and youth initiation. Major medical organizations (ACS, AHA) acknowledge e-cigarettes may be less harmful than cigarettes but don't recommend them as first-line cessation tools. FDA-approved medications (varenicline, NRT, bupropion) remain the standard of care.
Even low-dependence smokers (FTND 0–2) benefit from pharmacotherapy — NRT approximately doubles quit rates across all dependence levels. However, low-dependence smokers also have reasonable quit rates with behavioral support alone (~14–20%). The decision depends on patient preference, prior quit attempts (those who've failed behavioral-only approaches should try medication), and clinical judgment. Brief NRT (gum, lozenge) is often sufficient for low-dependence smokers who opt for pharmacotherapy.